Drug Profile
LAQ 824
Alternative Names: Histone deacetylase inhibitors - Novartis; NVP-LAQ824Latest Information Update: 19 Jul 2010
Price :
$50
*
At a glance
- Originator Novartis
- Class Antineoplastics
- Mechanism of Action Histone deacetylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Jul 2010 Discontinued - Phase-I for Cancer in USA (unspecified route)
- 25 May 2005 Suspended - Phase-I for Cancer in USA (unspecified route)
- 07 Dec 2004 A preclinical study has been added to the Cancer pharmacodynamics section